Isocitrate Dehydrogenase Gene Mutation

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
2 programs
2
HMPL-306Phase 11 trial
HMPL-306Phase 11 trial
Active Trials
NCT04762602Terminated42Est. Feb 2025
NCT04764474Terminated46Est. Jan 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HutchmedHMPL-306
HutchmedHMPL-306

Clinical Trials (2)

Total enrollment: 88 patients across 2 trials

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Start: Apr 2021Est. completion: Jan 202546 patients
Phase 1Terminated

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Start: Feb 2021Est. completion: Feb 202542 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space